Emerging Biomarkers During Clinical Development of Anti-CTLA4 Antibody Therapy
Authors:
- 14 November 2014
- book chapter
- Published by Springer Nature
- p. 427-439
Abstract
No abstract availableKeywords
This publication has 86 references indexed in Scilit:
- Facing the dawn of immunotherapy for hepatocellular carcinomaJournal of Hepatology, 2013
- Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II studyAnnals of Oncology, 2013
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- Ipilimumab (MDX-010) in the treatment of non-small cell lung cancerExpert Opinion on Biological Therapy, 2012
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic MelanomaNew England Journal of Medicine, 2011
- Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic AdenocarcinomaJournal of Immunotherapy, 2010
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- A Pilot Study of CTLA-4 Blockade after Cancer Vaccine Failure in Patients with Advanced MalignancyClinical Cancer Research, 2007
- High-Dose Recombinant Interleukin 2 Therapy for Patients With Metastatic Melanoma: Analysis of 270 Patients Treated Between 1985 and 1993Journal of Clinical Oncology, 1999
- CTLA-4: a negative regulator of autoimmune disease.Journal of Experimental Medicine, 1996